FDA RWE Guidance Update | Genesis Research Group

First published: 11 October 2023
Updated: 21 September 2026

The FDA accepts real-world evidence (RWE) in regulatory decision-making for drugs, biologics, and medical devices, but only when the underlying real-world data (RWD) source has been evaluated as fit for purpose, the study protocol and statistical analysis plan were finalized before the study started, the data handling is fully traceable, and patient-level data can be made available where applicable.

Since the FDA’s 2023 real-world evidence guidance for drugs and biologics, five further FDA and ICH guidance developments have refined what regulatory-grade RWE looks like in practice: two finalized guidances on assessing data quality from registries (December 2023) and from electronic health records and medical claims data (July 2024), a March 2024 draft on non-interventional studies, the ICH M14 guidance on safety studies (finalized by the FDA in March 2026), and a December 2025 medical device guidance that, most notably, allows aggregate or de-identified real-world data in some cases.

Key takeaways: FDA real-world evidence guidance updates

The FDA’s 2023 real-world evidence guidance for drug and biological products set the current regulatory baseline: documented RWD source evaluation, pre-registered protocol, traceable data handling, and patient-level data availability where applicable.
December 2023 final guidance addressed how to assess registries as an RWD source, and July 2024 final guidance did the same for electronic health records and medical claims data, both aimed at strengthening data quality assessment for a specific source type ahead of a regulatory submission.
March 2024 draft guidance addressed non-interventional studies using real-world data specifically, and remains in draft as of mid-2026.
The ICH M14 guidance, first issued in draft in July 2024, set international principles for non-interventional pharmacoepidemiological safety studies that use RWD; the FDA adopted the final version in March 2026, replacing both the 2024 draft and the FDA’s older 2013 pharmacoepidemiology safety guidance.
A separate draft guidance on externally controlled trials, which predates the 2023 baseline (first published January 2023), remains in draft more than three years on, even though externally controlled studies already feature in real FDA drug approvals.
December 2025 final guidance for medical devices allows aggregate or de-identified data in some cases, a first for the FDA’s real-world evidence framework, though not yet extended to drug and biologic regulatory decision-making.
Alongside that guidance, the FDA published 73 real examples of RWE-supported marketing authorizations from FY2020 to FY2025, but these are device examples specifically; drug and biologic sponsors have their own equivalent resource in the FDA’s regularly updated catalogue of CDER drug approvals that used real-world evidence, which includes precedent for registry-based, cohort, and externally controlled study designs.

Why staying current with FDA real-world evidence guidance matters

In August 2023, the FDA finalized its guidance on the use of real-world data (RWD) and real-world evidence (RWE) to support regulatory decision-making for drug and biological products. Since then, the agency has kept moving: four further drug and biologic-specific real-world evidence guidance documents followed between December 2023 and March 2026, addressing everything from registry and EHR/claims data quality to non-interventional study design and safety-study methodology, and a finalized RWE guidance for medical devices arrived in December 2025 that removed the FDA’s long-standing requirement to submit identifiable individual patient data, replacing it with case-by-case review of aggregate or de-identified data.

The FDA has stated it intends to consider similar updates for drug and biologic guidance, though that hasn’t happened yet. The gap matters in practice: since 2016, only 35 drugs, biologics, and vaccines have included RWE in their applications, compared with more than 250 device authorizations over the same period, and an evidence team working from the 2023 guidance alone, without tracking what’s changed since, is missing well over two years of relevant regulatory movement.

What the FDA’s 2023 real-world evidence guidance requires

The FDA’s core expectations from the 2023 real-world evidence guidance haven’t changed, and they remain the regulatory baseline for any RWD-supported submission for drugs and biologics.

Sponsors are expected to:

Finalize the study protocol and statistical analysis plan before study implementation begins.
Register the protocol in a public repository.
Document the roles and responsibilities of any third parties involved in the study.
Maintain audit trails of the real-world data throughout.
Ensure patient-level data is available for submission to the FDA where applicable.

Underneath all five of those requirements sits one theme: transparency around how the real-world data source itself was chosen. Sponsors are expected to run a systematic, documented evaluation of candidate RWD sources, justify why a given source was selected or excluded for the specific research question at hand, and be ready to discuss that fit-for-purpose assessment with the FDA before the study starts.

A rationale built after results are already in hand does not meet the FDA’s regulatory-grade bar, however sound the underlying methodology turns out to be. The same fit-for-purpose logic carries over directly into an HTA submissions and value dossiers, where reviewers are asking the same question about data source justification.

What’s changed in FDA real-world evidence guidance since 2023

Four more guidance documents specific to drugs and biologics followed the 2023 guidance, two of them aimed squarely at data quality for a specific RWD source. A fifth, on externally controlled trials, actually predates the 2023 guidance and is still in draft today. A separate medical device guidance then arrived in December 2025.

One guidance document actually predates the 2023 baseline, and is still unresolved. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products was first published as draft guidance in January 2023, ahead of the general 2023 RWE guidance, and remains in draft more than three years later. It sets out FDA considerations for using an external control arm, a group of people outside the trial, treated or untreated, from an earlier time or the same time period, to support evidence of a drug’s effectiveness or safety. Despite the guidance’s draft status, externally controlled trials already appear in real FDA drug approvals, including Gamifant (emapalumab-lzsg) and Kygevvi (doxecitine and doxribtimine), both in the FDA’s own catalogue of CDER drug approvals that used real-world evidence.

December 2023 brought the finalized Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products. This guidance gives sponsors FDA-specific considerations for designing a new registry, or using an existing one, as the RWD source behind a study of a drug’s effectiveness or safety, separate from the broader fit-for-purpose principles in the 2023 guidance.

March 2024 brought Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products. This guidance is aimed specifically at sponsors planning to submit a non-interventional study, meaning a study where the treatment assignment happens as part of routine clinical practice rather than being randomized by the study design, to help demonstrate substantial evidence of effectiveness or safety. It sets out how the FDA expects non-interventional study design choices, from cohort definition to confounding control, to be justified and documented.

July 2024 brought the finalized Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products, finalizing a draft first issued in September 2021. Alongside the December 2023 registries guidance, this gives sponsors FDA-specific expectations for the two most commonly used RWD source types, rather than relying solely on the general fit-for-purpose principles in the 2023 guidance.

July 2024 to March 2026: ICH M14. The FDA and its international counterparts first issued ICH M14 as draft guidance on the general principles for planning, designing, and analyzing pharmacoepidemiological studies that use RWD for safety assessment. Unlike the FDA-specific guidance documents, this one is an internationally harmonized standard developed through the International Council for Harmonisation, meaning sponsors working across multiple regulatory jurisdictions get one consistent set of expectations for RWD-based safety studies rather than a different standard per country. The FDA adopted the final version, retitled General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines, in March 2026, replacing the 2024 draft and the FDA’s 2013 pharmacoepidemiology guidance.

December 2025 brought the finalized Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices, superseding the 2017 device guidance. The most consequential change: sponsors can now use aggregate or de-identified data in some cases, rather than being expected to secure access to identifiable patient-level data as a condition of using a given RWD source. RWE is evaluated case by case on whether it is scientifically sound and fit for its intended purpose. Alongside the guidance, the FDA published 73 real examples of RWE-supported marketing authorizations from FY2020 to FY2025, spanning a range of device types and giving sponsors a growing bank of precedent to reference when building their own submissions.

This device-specific change still matters for drug and biologic sponsors preparing an FDA submission or HTA submission, even though it doesn’t apply to them directly. It signals where the FDA’s comfort level with real-world data flexibility is heading, well before that flexibility necessarily reaches drug and biologic regulatory decision-making.

Not sure whether your current real-world data source and study design would meet the FDA’s fit-for-purpose bar? Talk to our RWE team

What FDA real-world evidence guidance updates mean for your regulatory strategy

None of the 2024 or 2025 updates change the fundamentals of the FDA’s 2023 real-world evidence guidance. What they change is the range of study designs and data access models the agency is willing to consider regulatory-grade, and that range is expanding faster than most internal evidence teams have time to track guidance-by-guidance. A team relying on a single RWD vendor’s definition of “fit for purpose” is working from a narrower set of real-world data options than the FDA itself is now willing to accept, particularly as medical device guidance signals more flexibility ahead.

Genesis Research Group is a data-agnostic real-world evidence and HEOR consultancy, not tied to a single dataset, vendor, or methodology, and has worked across more than 40 unique real-world data sources on behalf of clients preparing FDA submissions and HTA submissions alike.

That experience includes designing and conducting external control arm studies for regulatory submission, post-authorization safety studies, and RWD-supported orphan drug designations: specific study types that speak directly to what sponsors are actually searching for. That range matters here specifically: the right data source for a regulatory-grade RWE study changes with each new piece of guidance, and being able to select from a wide field of sources and study designs, rather than justifying whichever one is already on hand, is what keeps a fit-for-purpose assessment genuine rather than a formality.

It’s also why many clients bring Genesis in through a Flexible Integrated Team engagement rather than a single fixed-scope study, so the same team can adapt the data source and study design as guidance evolves, instead of re-scoping from scratch each time.

FAQs: FDA real-world evidence guidance

These are the questions that come up most often when sponsors are trying to work out where their current real-world evidence approach stands against the FDA’s latest regulatory guidance.

What is real-world evidence, in the FDA’s own terms?

Real-world evidence (RWE) is clinical evidence about a medical product’s usage, benefits, or risks, derived from analysis of real-world data (RWD): data collected outside traditional clinical trials, such as electronic health records, claims data, and registries.

Does the FDA require patient-level data for every RWE submission?

For drug and biological products, the 2023 guidance still expects individual patient-level data to be submitted where applicable, though not necessarily identifiable data. The December 2025 medical device guidance goes further for devices, formally allowing aggregate data and removing the requirement to submit identifiable individual patient data in some circumstances. The FDA has stated it intends to consider similar updates for drug and biologic guidance, but that hasn’t happened yet.

Has the FDA issued guidance on assessing real-world data quality by source type?

Yes. The FDA has finalized source-specific guidance for two of the most commonly used RWD types: registries (December 2023) and electronic health records and medical claims data (July 2024). Both sit alongside the FDA’s broader 2023 real-world evidence guidance and give sponsors more specific expectations for the particular data source behind a study, rather than relying on the general fit-for-purpose principles alone.

Does the FDA have guidance on externally controlled trials?

Only in draft. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products has been in draft since January 2023 and hasn’t been finalized. That hasn’t stopped externally controlled trials from supporting real FDA drug approvals in the meantime, including Gamifant (emapalumab-lzsg) and Kygevvi (doxecitine and doxribtimine).

What is a ‘fit-for-purpose’ data source assessment?

It’s a systematic, documented evaluation of whether a given RWD source is relevant and reliable enough to answer the specific research question a study is designed around, conducted, and justified before the study begins.

How is a ‘regulatory-grade’ RWE study different from a general RWD analysis?

A regulatory-grade study is built to the FDA’s transparency and reproducibility standards from the outset: a pre-registered protocol and statistical analysis plan, documented third-party roles, maintained audit trails, and a defensible fit-for-purpose data source justification.

Does the ICH M14 guidance replace FDA-specific RWE guidance?

No. ICH M14 sets international principles specifically for non-interventional pharmacoepidemiological safety studies using RWD, finalized by the FDA in March 2026. It adds one internationally consistent layer of expectations alongside the FDA’s own guidance for drug and biological products, without changing that guidance’s core requirements.

Related Reading: For a closer look at what ‘regulatory-grade’ real-world evidence actually requires in practice, see our companion guide: What Is Regulatory-Grade RWE? For more on Genesis’s approach to real-world evidence generally, see Real-World Evidence Services, or browse the Genesis Insights hub.

Want to pressure-test your RWD source and strategy before your next submission?

A regulatory-grade RWE strategy depends on whether the source, study design, protocol, analysis plan, and audit trail can withstand review for the question you need to answer. Genesis can help you assess candidate real-world data sources, identify evidence gaps, and design a fit-for-purpose approach before critical submission decisions are locked in.

Ask our RWE team